manner. PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) will also be used to form mixed micelles and determine PTX pH-dependent release profiles from these micelles. We have hypothesized that mixed polymeric micelles composed of PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) would have a composite release profile for PTX, reflecting the rate of hydrazone hydrolysis of LEV-PTX and 4AB-PTX in mixed polymeric micelles (Fig. 1) . If successful, we anticipate that these polymeric micellar delivery system offer new prospects for moderating the pH-dependent release of PTX and for enhancing its pharmacokinetic and pharmacodynamic properties, aiming for advances in cancer therapy for solid tumors.
Materials & Methods

Materials
-methoxy--amino-poly(ethylene glycol) (PEG-NH 2 ) (M n 12,000 g/mol, PDI = 1.03) was purchased from NOF Corporation (Tokyo, Japan). PTX was obtained from LKT laboratories Inc 
Methods
Synthesis of amphiphilic diblock copolymer PEG-PBLA
PEG-PBLA was synthesized as previously reported [21] [22] . Briefly, β-benzyl-L-aspartate Ncarboxyanhydride (BLA-NCA) was prepared using Fuchs-Farthing method, triphosgene 5.76 g (19.4 mmol) was added to 10 g (44.8 mmol) of β-benzyl-L-aspartate in dry tetrahydrofuran (THF) (150 mL), and the reaction was allowed to proceed at 40 °C until the solution became clear. BLA-NCA was purified by recrystallization from hexane and purity was confirmed by measuring its melting point at 129.5 o C. Ring opening polymerization of BLA-NCA (1.7 g, 6.82 mmol) was initiated from the terminal primary amine group of PEG-NH 2 (2.0 g, 0.16 mmol).
The polymerization was carried out under argon atmosphere in anhydrous DMSO (7.0 mL) at 40 C for 2 days. PEG-PBLA was obtained after precipitation from diethyl ether followed by freeze drying from benzene.
Synthesis of PEG-p(Asp-Hyd)
PEG-p(Asp-Hyd) was synthesized as previously reported [17] [18] 20] . Briefly, PEG-PBLA (1.0 g, 0.05 mmol) was dissolved in anhydrous N,N-dimethylformamide (DMF) (10 mL), and anhydrous hydrazine (1.2 eq with respect to benzyl groups) was added to the polymer solution under argon atmosphere. The reaction was allowed to proceed at 40 o C for 1 hr followed by polymer precipitation in diethyl ether. PEG-p(Asp-Hyd) was dialyzed against 0.25% ammonia solution then 0.025% ammonia solution and freeze-dried to obtain the product, PEG-poly(AspHyd). The structure of PEG-poly(Asp-Hyd) was confirmed using 1 H NMR (500MHz, DMSOd 6 ).
Synthesis of PEG-p(Asp-Hyd-LEV) and PEG-p(Asp-Hyd-4AB)
The pH labile hydrazone bond was formed via the reaction of the hydrazine groups on the PEGp(Asp-Hyd) with the ketone group on LEV or 4AB, resulting in the formation of PEG-p(AspHyd-LEV) or PEG-p(Asp-Hyd-4AB), respectively. PEG-p(Asp-Hyd) (750 mg , 0.046 mmol)
was dissolved in 15 mL anhydrous dimethyl sulfoxide (DMSO). 4AB or LEV (1.2 eq with respect to hydrazide group) was dissolved in anhydrous DMSO and added to the polymer solution under argon. The reaction was allowed to proceed for 48 hr at 45 o C. PEG-p(Asp-Hyd-LEV) or PEG-p(Asp-Hyd-4AB) was collected from diethyl ether, solubilized in DMF, and dialyzed against DMF using regenerated cellulose (MWCO: 3,000 g/mol). Polymers were collected from diethyl ether and then freeze dried from benzene.
Synthesis of PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX)
PEG or PEG-p(Asp-Hyd-4AB-PTX) was collected by evaporating DCM, and the residue was diluted in 5.0 mL DMF. The polymer solution was dialyzed against 1.0 L DMF (DMF was changed 3 times) using regenerated cellulose (MWCO: 6-8000 g/mol). The polymer was precipitated in diethyl ether, freeze-dried from benzene, and the product was collected as a white powder. The structure and the degree of substitution of PTX on PEG-p(Asp-Hyd-LEV-PTX) or PEG-p(AspHyd-4AB-PTX) was confirmed by 1 H NMR (500MHz, DMSO-d 6 ), and their purity was confirmed by reverse-phase HPLC. (C-19). column oven and a SPD-M20A diode array detector.
Synthesis of LEV-PTX and 4AB-PTX
Reverse-phase HPLC
NMR spectroscopy
NMR measurements were performed on UNITY INOVA NMR spectrometers (Varian, USA) model operating at 500 MHz normal proton frequencies. Sample temperature was regulated for all measurements and was set at 80 o C. The spectrometer was equipped with FTS Systems preconditioning device (composed of refrigerating unit, internal temperature controller and inclusion transfer line). Acquisition parameters were adjusted on a case-by-case basis to provide adequate signal-to-noise and spectral resolution, the latter typically at 0.5 and 4.2 ppB/point for 1D high-resolution 1 H and 13 C spectra, respectively. Carbon-13 spectra were acquired with proton decoupling. All 1 H and 13 C spectra were referenced with respect to TMS at 0.0 ppm. 
Preparation and characterization of PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-
Hyd
In vitro drug release experiments
PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) micelles were prepared as described above (section 2.2.8), and a sample of 2.5 mL was loaded into a Slide-A-Lyzer® 
In vitro cytotoxicity experiments
The CellTiter-Blue 
Data analysis
Statistical analysis was performed using one-way ANOVA at 5 % significance level combined with Tukey's Multiple Comparison Test or t-test at 5 % significance level. IC 50 was calculated
In vitro drug release experiments on PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) micelles and their mixed polymeric micelles
The (Fig. 7A) .
However, the release profiles of LEV-PTX from mixed polymeric micelles at a 1:5 ratio at pH 5.0 was statistically significantly lower than its release from the PEG-p(Asp-Hyd-LEV-PTX) micelles or mixed polymeric micelles at a 1:1 ratio (Fig. 7A) . At pH 7.4, no significant difference was noticed among the release profiles of LEV-PTX from all polymeric micelles ( 
Discussion
Polymeric micelles are gaining increasing attention in the field of anti-cancer drug delivery, owing to prospects for drug solubilization and more recently for controlled drug release, which in concert with the EPR effect could permit prolonged circulation in blood, preferential accumulation at solid tumors, and drug release, triggered by an acidic extracellular milieu often found at solid tumors or by low pH 4-5 encountered after cellular entry in the endosomes/lysosomes [17] [18] [19] [20] . PTX lacks an aldehyde or ketone functional group for hydrazone chemistry, and ester prodrugs of PTX usually involve its C-2ˊ-OH-position [24] . Thus, we have used an aliphatic linker, LEV or an aromatic linker 4AB, as a spacer group on PEG-p(Asp-Hyd) ( Fig. 1 and 3) , gaining 100% substitution of LEV or 4AB on PEG-p(Asp-Hyd) based on 1 H NMR spectroscopy (Fig. 4) . PTX reacts with PEG-p(Asp-Hyd-LEV) or PEG-p(Asp-Hyd-4AB) through its C-2ˊ-OH-position by DIC/DMAP coupling, resulting in PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) (Fig. 3) , with degrees of drug substitution at 37.5 and 87.5%, respectively, based on 1 H NMR spectroscopy (Fig. 4) . It is anticipated that the degrees of PTX can be varied by using varied ratios of PTX to PEG-p(Asp-Hyd-LEV-PTX) or PEG-p(Asp-Hyd-4AB-PTX). We note that LEV-PTX and 4AB-PTX react poorly with PEG-p(Asp-Hyd), resulting in low degrees of PTX substitution (data not shown), and we have not pursed this pathway toward PEG-p(Asp-Hyd-LEV-PTX) or PEG-p(Asp-Hyd-4AB-PTX).
DLS measurements have provided evidence that PEG-p(Asp-Hyd-LEV-PTX) or PEG-p(AspHyd-4AB-PTX) assembles into unimodal polymeric micelles (Fig 6.) . resulting in increased core hydrophobicity. While major differences between PEG-p(Asp-Hyd-4AB-PTX) micelles and PEG-p(Asp-Hyd-LEV-PTX) micelles emerge in vitro, it is expected that these differences will be less in vivo, where both polymeric micelles will undergo disassembly into unimers, which will be exposed to water and hydrolysis.
We have hypothesized that PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX) will co-assemble into mixed polymeric micelles, affecting drug release. At a 1:1 ratio, the release of LEV-PTX is similar to the release pattern of LEV-PTX for PEG-p(Asp-Hyd-LEV-PTX) micelles (Fig. 7) , noting that the total quantity of LEV-PTX was equivalent for all the samples. Similarly, it will be interesting to study whether the anti-angiogenesis activity of PTX has been Previous studies have shown that the hydroxyl group at the 2′-position of PTX (Fig. 2) is required for cytotoxicity [24, 26] .
Current commercial and new PTX formulations focus on exploiting its mitotic inhibitory effect, which requires maximum tolerated doses of PTX to be delivered on a rotating schedule. The new paradigm shift in cancer therapy has indicated that PTX at low doses can be a potent antiangiogenic agent. Thus, the focus of our work and the proof of concept experiments conducted by our lab are looking to produce PTX formulations that will highlight its anti-angiogenic effects which can be augmented by administering comparatively low doses of PTX over. Traditional polymer chemistry would accomplish this by creating a library of polymers with different number of PTX attached to the backbone. Our system allows us to minimize the synthesis needed to two set of polymer constructs. By mixing these polymers constructs in different ratios to form polymeric micelles we can achieve controlled release of PTX under acidic conditions.
Thus, enabling us to elegantly tailor concentration of PTX under specified set of conditions.
Further studies are planned to test the in vivo efficacy of these systems in mice tumor models to further validate this approach. The ultimate advantage of successfully implementing this kind of a formulation will allow patients to have continuous therapy with much lower side effects leading to higher patient compliance rates and better quality of life.
Conclusions
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